Abrinica, Clyde .
HRN: 27-22-75 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/30/2025
LEVOFLOXACIN 5MG/ML, 100ML (VIAL)
09/30/2025
10/14/2025
IV
70mg
Q12H
Hospital Acqiured Pneumonia, UTI
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes